tradmap

AXGN Axogen, Inc.

$49.85 +0.97%

Data as of close

Healthcare · Electromedical & Electrotherapeutic Apparatus

Axogen, Inc. (AXGN) is a healthcare company in the Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $3.0 billion. Shares last traded at $49.85, 8.5% below their 52-week high. Over the past year the stock is up 119.7%. Net profit margin is -12.0%, below the peer median of -10.0%. Revenue grew 20.2% year over year.

Market Cap
$3.0B
Shares Out
59.7M
EPS (TTM)
-$0.65
P/E (TTM)*
—
P/S Ratio
11.16
P/B Ratio
6.00
Dividend / Share
—
Dividend Yield
—
52-Week High
$54.50
52-Week Low
$21.93
Volume (venue)
110,761
Avg Vol (3m, venue)
89,937.381

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+31.13%
1M
+33.40%
3M
+8.53%
6M
+16.91%
YTD
+52.33%
1Y
+119.75%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
74.55
SMA (50)
$42.84
SMA (200)
$39.66
Price vs SMA50
+16.37%
Price vs SMA200
+25.69%
ATR (14)
$2.30

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$267M
Net Income
-$32M
Gross Margin
74.2%
Operating Margin
-5.2%
Net Margin
-12.0%
Return on Equity
-6.4%
Return on Assets
-5.8%
Current Ratio
12.02
Debt / Equity
0.00
Revenue Growth (YoY)
+20.2%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 $0.04 2026-10-28
Q2 2026 -$0.03 2026-07-29
Q1 2026 -$0.38 2026-04-28
Q4 2025 (derived) -$0.28 2026-02-24
FY 2025 -$0.34 2026-02-24
Q3 2025 $0.01 2025-10-29

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Electromedical & Electrotherapeutic Apparatus peers

AXGN vs 14 industry peers (Electromedical & Electrotherapeutic Apparatus), by market cap. Data as of close

P/S vs peers
11.16 / 2.65 med
+322% premium
Net margin vs peers
-12.0% / -10.0% med
below median
1–14 of 14
MDTMedtronic$127.0B24.283.3813.9%+2.86%
LIVNLivanova Plc$4.4B23.443.0012.8%+1.58%
ITGRInteger Holdings Corp$4.3B41.502.365.7%-0.02%
AXGNAxogen, Inc.$3.0B—11.16-12.0%+0.97%
TMDXTransmedics Group, Inc.$2.3B15.213.4522.7%+1.05%
CNMDConmed Corp$1.4B29.481.013.4%+5.20%
CBLLCeribell, Inc.$1.0B—10.15-64.7%+1.51%
INMDInmode Ltd.$867M9.242.3425.3%+3.56%
CVCapsoVision, Inc$337M———-1.32%
ELMDElectromed, Inc.$224M19.853.0415.3%-0.28%
FOCLEDAP TMS SA$161M—2.29-41.5%+2.26%
VANIVivani Medical, Inc.$99M—207.94—+0.00%
STXSStereotaxis, Inc.$88M—2.93-74.2%+2.76%
NRXSNeuraxis, INC$84M———-6.91%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.